Optimal model establishment of whole-process management data for CAR-T therapy in China—how should this be done?

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cellular & molecular immunology 2022-01, Vol.19 (1), p.122-124
Hauptverfasser:	Li, Xiaolei, Dai, Hanren, Li, Xian, Li, Ping, Qian, Wenbin, Liang, Aibin, Han, Weidong
Format:	Artikel
Sprache:	eng
Schlagworte:	631/250/2152/1566/1618 692/4028/67/580 Algorithms Antibodies Apheresis Biomedical and Life Sciences Biomedicine China Clinical medicine Clinical trials Comment FDA approval Hematology Hospitals Immunology Immunotherapy, Adoptive Laboratories Lymphocytes Manufacturing Medical Microbiology Microbiology Multidisciplinary teams Patients Quality standards Receptors, Chimeric Antigen Task forces Vaccine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!